Study S001394

EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

ClinicalTrials.gov record

Registration

Registration: NCT05663515
Acronym: EXCEED
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 24000
Start: 2024-09-30
Primary completion: 2026-10-01
Lead sponsor: AstraZeneca
Conditions: Pancreatic Cancer
Interventions: DRUG:Exenatide; DRUG:Non-GLP-1 RA based glucose lowering drugs
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Incidence rate of primary diagnosis of pancreatic cancer among exenatide exposed population [Follow-up starts from the index date to the study completion, an average of 1.5 years or less]
Hazard ratio of primary diagnosis of pancreatic cancer among exenatide exposed population [Follow-up starts from thr index date to the study completion, an average of 1.5 years or less]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.